Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1997-2-26
|
pubmed:abstractText |
Combined chemotherapy with 5-FU or UFT and CDDP was performed in 22 cases with inoperable advanced or recurrent colorectal cancer. When in hospital, 5-FU 375 mg/m2/day c.i.v.. (days 1-7) and CDDP 3.75 or 7.5 mg/m2/day i.v.. (days 1-5) were administered for as many weeks as possible, while for outpatients UFT 450 mg/m2/day po (days 1-7) and CDDP 3.75 or 7.5 mg/m2/day div. (days 2 and 5 were given for as many weeks as possible. The performance status (PS) of the cases at the beginning of the chemotherapy was lower than 3 in 15 patients and over 3 in 7 patients. The response rate in cases with no history of systemic 5-FU chemotherapy was 30%, and the mean NC period in all cases of NC was 170 days. Half of the symptoms were improved in cases with some symptoms before chemotherapy, and half of the patients whose PS was over 3 could leave the hospital after chemotherapy. Toxicity was seen in 80% of the cases, but those over grade 3 were seen in only 2 cases. The mean administration period of the chemotherapy was 180 days, which shows a high compliance of the method.
|
pubmed:language |
jpn
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/UFT(R) drug,
http://linkedlifedata.com/resource/pubmed/chemical/Uracil
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0385-0684
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
55-60
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9020946-Administration, Oral,
pubmed-meshheading:9020946-Adult,
pubmed-meshheading:9020946-Aged,
pubmed-meshheading:9020946-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9020946-Cisplatin,
pubmed-meshheading:9020946-Colonic Neoplasms,
pubmed-meshheading:9020946-Drug Administration Schedule,
pubmed-meshheading:9020946-Drug Combinations,
pubmed-meshheading:9020946-Female,
pubmed-meshheading:9020946-Fluorouracil,
pubmed-meshheading:9020946-Humans,
pubmed-meshheading:9020946-Infusions, Intravenous,
pubmed-meshheading:9020946-Male,
pubmed-meshheading:9020946-Middle Aged,
pubmed-meshheading:9020946-Neoplasm Recurrence, Local,
pubmed-meshheading:9020946-Rectal Neoplasms,
pubmed-meshheading:9020946-Tegafur,
pubmed-meshheading:9020946-Uracil
|
pubmed:year |
1997
|
pubmed:articleTitle |
[Low-dose cisplatin added to continuous infusion of 5-fluorouracil or oral administration of UFT for inoperable advanced or recurrent colorectal cancer].
|
pubmed:affiliation |
Division of Surgery, Tokyo Metropolitan Komagome Hospital.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Case Reports
|